These findings together with observations that metformin has beneficial effects in prostate cancer, and the data showing that metformin targets the MID1-α4/PP2A complex let us to hypothesize that metformin might interfere with AR protein synthesis via this complex and thus inhibit tumor properties of prostate cancer cells. This evidence concerns the gene PTPA and neoplasm.